Erzincan, Selen G.Varol, Fusun G.Inan, CihanSayin, N. Cenk2024-06-122024-06-1220180143-40041532-3102https://doi.org/10.1016/j.placenta.2017.12.015https://hdl.handle.net/20.500.14551/23368To investigate the levels of Prokineticin-1 (PROK1) and matrix metalloproteinase-2 (MMP-2) in second-trimester amniotic fluid (AF). AF samples were investigated in 81 patients. AF-PROK1 and AF-MMP-2 were not significantly associated with adverse pregnancy outcomes (preeclampsia, intrauterine growth retardation, spontaneous preterm birth, gestational diabetes, gestational hypertension). AF-PROK1 levels in patients with abnormal first-trimester screening were significantly higher than those who underwent amniocentesis due to abnormal second-trimester screening tests (p = .04). AF-PROK1 or AF-MMP-2 do not have a role in the prediction of adverse pregnancy outcomes. (c) 2017 Elsevier Ltd. All rights reserved.en10.1016/j.placenta.2017.12.015info:eu-repo/semantics/closedAccessProkineticin 1Metalloproteinase (MMP)-2Amniotic FluidPlacentaAdverse Pregnancy OutcomesEndothelial Growth-FactorEg-VegfArticle622527Q1WOS:0004243718000042-s2.0-8503882408729405963Q1